Article Information
History
- July 18, 2024.
Article Versions
- Version 1 (October 27, 2023 - 11:01).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Novia Syari Intan1,
- Revata Utama1,*,
- Dewi Wulandari2,7,
- Reiva Wisdharilla2,7,
- Shafira Mutia Khanza1,
- Muhamad Rifki Ramadhan1,
- Indah Suci Widyahening3,
- Neni Nurainy4,
- Rini Mulia Sari5 and
- Andrijono6,7
- 1Nusantics, PT. Riset Nusantara Genetika, Pulomas Barat No.Kav. 88, 13210, East Jakarta, Indonesia
- 2Department of Clinical Pathology, Faculty of Medicine, Universitas Indonesia, Salemba Raya 6, 10430, Central Jakarta, Indonesia
- 3Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Salemba Raya 6, 10430, Central Jakarta, Indonesia
- 4Translational Development of Life Science Product Division, PT Bio Farma, Pasteur 28, 40161, Bandung, Indonesia
- 5Surveillance and Clinical Research Division, PT Bio Farma, Pasteur 28, 40161, Bandung, Indonesia
- 6Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Salemba Raya 6, 10430, Central Jakarta, Indonesia
- 7Cipto Mangunkusumo Hospital, Pangeran Diponegoro 71, 10430, Central Jakarta, Indonesia
- ↵*CORRESPONDING AUTHOR:
Revata Utama, Postal Address: Nusantics, PT. Riset Nusantara Genetika, Pulomas Barat No.Kav. 88, 13210, East Jakarta, Indonesia, Telephone Number: (+62) 811-8135-689. E-mail: revata{at}nusantics.com
Posted July 18, 2024.
Urinary high-risk HPV DNA detection to enhance cervical cancer screening in developing countries
